Objective-Vascular endothelial growth factor (VEGF) has been identified as a crucial regulator of physiological and pathological angiogenesis. Among the intracellular signaling pathways triggered by VEGF, activation of the calcineurin/ nuclear factor of activated T cells (NFAT) signaling axis has emerged as a critical mediator of angiogenic processes. We and others previously reported a novel role for the plasma membrane calcium ATPase (PMCA) as an endogenous inhibitor of the calcineurin/NFAT pathway, via interaction with calcineurin, in cardiomyocytes and breast cancer cells. However, the functional significance of the PMCA/calcineurin interaction in endothelial pathophysiology has not been addressed thus far. Approach and Results-Using in vitro and in vivo assays, we here demonstrate that the interaction between PMCA4
A ngiogenesis, the formation of new blood capillaries from pre-existing vessels, is a physiological process essential for proper embryonic development, organ growth, and tissue repair. 1 Blood vessels respond to a tightly regulated interplay of pro-and antiangiogenic factors to ensure proper vascular remodeling during development, wound healing, and pregnancy. 1 Abnormal growth of blood vessels, caused by deregulation of this process, plays a critical role in the pathophysiology of several human diseases, including tumor growth and metastasis, proliferative retinopathies, age-related macular degeneration, neovascular glaucoma, ischemic disorders, and rheumatoid arthritis. 2 The proangiogenic factor vascular endothelial growth factor (VEGF) and its tyrosinekinase receptor, VEGF-R, have been identified as crucial regulators of both physiological and pathological angiogenesis. 3 VEGF activates several intracellular signal transduction pathways that trigger the angiogenic process. Among them, the calcineurin/nuclear factor of activated T cells (NFAT) signaling axis has emerged as a critical mediator of VEGFstimulated angiogenesis. [4] [5] [6] [7] Calcineurin is a serine/threonine phosphatase activated in response to increments in the intracellular calcium concentration. 8 The best characterized substrate of calcineurin is the NFAT family of transcription factors. 9 NFATs are synthesized as constitutively phosphorylated proteins that reside in the cytoplasm of the cell. In response to VEGF stimulation, calcineurin mediates dephosphorylation of NFATs, promoting their translocation into the nucleus. 4, 6, 7 Once in the nucleus, activated NFATs trigger the expression of endothelial target genes that participate in the formation of new blood vessels. [4] [5] [6] [7] The relevance of calcineurin/NFAT signaling to the progression of pathological angiogenesis highlights the clinical potential of this route for the design of therapeutic interventions aimed at the treatment of neovascular-associated human diseases. Inhibition of calcineurin activity with the immunosuppressant drug cyclosporine A (CsA) has been shown to significantly decrease VEGF-mediated angiogenesis in animal models. 5 However, long-term treatments with CsA are associated with undesirable side effects in patients precluding its use to treat chronic diseases including diabetic retinopathies and cancer. 10 It is therefore essential to characterize endogenous cellular inhibitors of calcineurin that are less toxic and could be more suitable for chronic inhibition of this pathway. Toward this goal, we have identified recently a novel inhibitory interaction between endogenous plasma membrane calcium ATPase (PMCA) proteins and calcineurin. 11, 12 PMCAs are high-affinity calcium pumps that extrude calcium from the cytosol to the extracellular medium. 13 In humans, PMCA proteins are encoded by 4 independent genes termed PMCA1 to 4. PMCA1 and 4 are expressed ubiquitously, whereas the expression of PMCA2 and 3 is restricted to specific cells and tissues. 13 It is thought that PMCAs inhibit the activity of calcium-dependent calcineurin by tethering it to small low-calcium microdomains created by the calcium extrusion activity of the pump. 14 We previously reported that PMCAs and calcineurin interact in endothelial cells 15 although the functional significance of this interaction in endothelial pathophysiology has not been described thus far. ) were coinfected with either Ad-LacZ or Ad-PMCA4 (MOI=50) for 24 hours, and then with Ad-NFAT-Luc (MOI=25) for an additional 24 hours. Infected cells were serum-starved in medium containing 0.5% fetal calf serum and left unstimulated (-) or treated with vascular endothelial growth factor (VEGF; 25 ng/mL) for 6 hours (VEGF). Mean±SE of 5 independent experiments are shown. *** indicates statistically significant differences (P≤0.005, according to Student t test) when comparing VEGF-stimulated HUVEC infected with Ad-LacZ vs those infected with Ad-PMCA4. C, Absence of PMCA4 expression in mouse lung endothelial cells (MLECs) isolated from PMCA4 knockout mice. A total of 0.5 μg of total RNA, isolated from MLECs obtained from PMCA4 wild-type (+/+) or knockout (−/−) mice, was retro-transcribed and the expression of the mouse PMCA4 and PMCA1 genes analyzed by semiquantitative polymerase chain reaction. Amplification of the housekeeping gene Hprt1 was used as a control. A figure representative of 3 independent experiments is shown. D, Targeted disruption of PMCA4 increases the activity of the calcineurin/NFAT pathway in MLECs. MLECs (3×10 5 ) isolated from PMCA4 wild-type (+/+) or knockout (−/−) animals were infected with Ad-NFAT-Luc (MOI=50) for 48 hours. After serum starvation in 0.5% fetal calf serum, cells were left unstimulated (-) or treated with VEGF (50 ng/mL) for 6 hours (VEGF) and luciferase activity was measured. Mean±SE of 5 independent experiments are shown. * indicates statistically significant differences (P≤0.05, according to Student t test) when comparing VEGF-stimulated PMCA4 (+/+) vs (−/−) MLECs.
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In this work, we demonstrate that the interaction between PMCA4 and calcineurin impairs endothelial cell motility and blood vessel formation in response to VEGF stimulation. An inhibitory effect of PMCA4 on VEGF-mediated activation of the calcineurin/NFAT signaling pathway, and the subsequent downregulation of RCAN1.4 and Cox-2 gene expression, is likely to account for angiogenesis inhibition.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

PMCA4 Negatively Regulates the Calcineurin/NFAT Pathway in VEGF-Activated Endothelial Cells
The role of PMCA as an inhibitor of the calcineurin/NFAT pathway in breast cancer cells 12 and cardiomyocytes 16 encouraged us to investigate whether this was also the case in VEGFactivated endothelial cells.
We ectopically expressed human PMCA4 in human umbilical vein endothelial cell (HUVEC) primary endothelial cells by infection with adenovirus Ad-PMCA4 ( Figure 1A ). To quantify the activity of the calcineurin/NFAT pathway, cells were also infected with a luciferase-based, NFAT-dependent adenoviral reporter vector (Ad-NFAT-Luc). Ectopic expression of PMCA4 significantly decreased (31.9% reduction, compared with cells infected with control Ad-LacZ) the VEGF-induced activation of the luciferase reporter ( Figure 1B) . Equivalent results were observed when the calcineurin/NFAT pathway was activated by stimulating the infected cells with phorbol 12-myristate 13-acetate (PMA) and the calcium ionophore A23187 ( Figure IA in the online-only Data Supplement).
To substantiate this observation, we analyzed the activity of the calcineurin/NFAT pathway in mouse lung endothelial cells (MLECs) isolated from PMCA4 knockout mice or from their corresponding wild-type littermates ( Figure 1C ). MLECs were infected with Ad-NFAT-Luc, and the calcineurin/NFAT pathway was activated by stimulation with VEGF ( Figure 1D ) or PMA+Io ( Figure IB in the online-only Data Supplement). In both cases, determination of luciferase activity in the infected cells revealed increased activation of the calcineurin/NFAT pathway in PMCA4-deficient cells compared with equivalent wild-type cells.
These results demonstrate that PMCA4 plays a substantial role as an endogenous inhibitor of the calcineurin/NFAT signal transduction pathway in activated endothelial cells.
PMCA4 Inhibits the Expression of NFAT-Dependent, Proangiogenic Genes in VEGF-Stimulated Endothelial Cells
Stimulation of endothelial cells with VEGF has been reported to activate the expression of NFAT-target genes, including RCAN1.4 and Cox-2, whose products actively participate in the onset of angiogenesis. [5] [6] [7] [17] [18] [19] The inhibitory effect produced by PMCA4 on the VEGF-induced activity of the calcineurin/NFAT pathway in endothelial cells prompted us to next examine the role of PMCA4 as a negative regulator of angiogenesis gene expression.
Ectopic expression of PMCA4 in HUVECs by infection with Ad-PMCA4 markedly inhibited the VEGF-dependent upregulation of RCAN1.4, both at the level of protein ( Figure 2A ) and mRNA ( Figure 2B ) expression (48.4% and 24.8% reduction, respectively). Similarly, VEGF-mediated upregulation of Cox-2 protein and mRNA was also diminished (52.1% and 29.4% reduction, respectively) by PMCA4 overexpression ( Figure IIA and IIB in the online-only Data Supplement). In contrast, expression of Cox-1, which is not regulated by the calcineurin/NFAT pathway, remained unchanged in PMCA4overexpressing cells ( Figure IIA in the online-only Data Supplement), highlighting the role of PMCA4 as a regulator of NFAT-driven genes.
To corroborate these findings, we next measured angiogenesis gene expression in endothelial cells in the absence of PMCA4. Transfection of HUVEC cells with a small interfering RNA pool directed to PMCA4 robustly silenced the expression of endogenous PMCA4 at the protein and mRNA level, without affecting PMCA1 expression ( Figure 2C ). PMCA4 silencing increased the expression of RCAN1.4 in both resting and VEGF-stimulated cells (1.9-and 3.86-fold increase, respectively, compared with a nontargeting small interfering RNA pool; Figure 2D ). Similarly, small interfering RNAmediated suppression of PMCA4 in HUVEC cells significantly increased the expression of the proangiogenic protein Cox-2 in VEGF-stimulated cells ( Figure IIIA in the onlineonly Data Supplement). Consistent with these results, analysis of PMCA4 -/-MLECs revealed higher levels of RCAN1.4 and Cox-2 protein, both in resting and VEGF-treated conditions, than those found in equivalent wild-type cells ( Figure 2E ; Figure IIIB in the online-only Data Supplement).
Taken together, these data indicate that inhibition of calcineurin/NFAT signaling by PMCA4 results in a downregulation of VEGF-induced RCAN1.4 and Cox-2 gene expression.
PMCA4 Reduces Endothelial Cell Migration and Blood Vessel Formation but Not Cell Proliferation
Blockage of the calcineurin/NFAT pathway by pharmacological doses of CsA has been shown to abrogate VEGF-driven endothelial cell migration, but not endothelial proliferation. 5 We thus performed wound-healing migration assays with cells overexpressing or lacking PMCA4 to investigate whether PMCA4 might play a role in the regulation of endothelial cell migration. Notably, Ad-PMCA4-infected HUVECs had a reduced ability to migrate into the wound compared with control-infected cells (39.8% reduction; Figure 3A ). Conversely, PMCA4 -/-MLECs displayed significantly increased cellular motility (66.6% increment over equivalent wild-type cells; Figure 3B ). These results imply that PMCA4 plays a negative role in the regulation of endothelial cell migration.
As VEGF-induced endothelial cell proliferation is an additional essential step in the progression of angiogenesis, we next evaluated whether PMCA4 participates in the regulation of this process. No significant differences in proliferation were found between PMCA4-expressing cells and control Ad-LacZinfected cells ( Figure 4A ). Because VEGF-dependent proliferation of endothelial cells requires activation of the mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinases 1 and 2 (Erk) signaling pathway, 20 we also tested whether PMCA4 modulates activation of Erk in HUVECs. Results showed that VEGF stimulation increased phosphorylation (activation) of Erk1/2 proteins to a similar extent in cells overexpressing either PMCA4b or β-galactosidase ( Figure 4B ). Consistent with this finding, HUVECs silenced for PMCA4 expression displayed similar levels of Erk1/2 phosphorylation to control (nontargeting small interfering RNA pool) cells after VEGF stimulation ( Figure 4C ). Taken together, these results indicate that PMCA4 does not participate in the regulation of endothelial cell proliferation.
Given that PMCA4 controls endothelial cell migration, we next addressed whether PMCA4 participates in the regulation of endothelial tube formation. Compared with controlinfected cells, basal tubular morphogenesis in an in vitro Matrigel assay was reduced significantly (34%) in HUVECs overexpressing PMCA4 ( Figure 5A ). Moreover, the additional VEGF-mediated tube formation was also clearly reduced by PMCA4 overexpression (Figure 5A ), suggesting that PMCA4 negatively regulates endothelial tube formation. To validate this observation in a more physiological setting, we performed in vivo angiogenesis assays in mice by subcutaneous injection of a mixture of low growth-factor Matrigel, VEGF, and an adenoviral vector (either Ad-PMCA4 or control Ad-Lacz). Consistent with our in vitro findings, Matrigel plugs containing Ad-PMCA4 produced fewer vessels (58.2% reduction) and had lower hemoglobin content (47.1% decrease) than control implants ( Figure 5B ), indicating that ectopic expression of PMCA4 impairs the angiogenic capability of endothelial cells in vivo.
To verify that our observations were not merely an effect of PMCA4 overexpression, we next assessed the involvement of endogenous PMCA4 in the regulation of angiogenesis. Knockdown of PMCA4 expression significantly increased HUVEC tubular morphogenesis, in both basal and VEGF-stimulated conditions (23.07% and 22.05% increase, respectively, compared with tube formation of control cells; Figure 5C ). Furthermore, vascularization and hemoglobin content of Matrigel plugs injected into PMCA4 -/mice was increased 3.1-and 2.3-fold, respectively, compared with plugs implanted in wild-type littermates ( Figure 5D ). Thus, these data strongly support a negative role for endogenous PMCA4 in blood vessel formation. To further reassure the in vivo significance of these observations, we evaluated the role of PMCA4 in blood vessel formation using the mouse hindlimb ischemia model of pathological angiogenesis. We induced unilateral ischemia by femoral artery ligation in the lower limb of PMCA4 wild-type or knockout animals and examined blood flow perfusion of the ischemic limb by laser Doppler perfusion imaging, at 5 and 14 days after surgery. Postischemic perfusion at both times was significantly higher in the ischemic limbs of PMCA4 knockout animals than in those of their wild-type littermates, suggesting that lack of PMCA4 results in a stronger postischemic revascularization ( Figure 6 ). No significant differences in blood flow were detected between the nonischemic contralateral limb of PMCA4 (+/+) and (−/−) animals.
Altogether, these results demonstrate a novel role for PMCA4 as a negative regulator of angiogenesis in vivo and suggest the involvement of PMCA4 in the onset of vascular pathologies that occur with angiogenesis.
Interaction Between PMCA4 and Calcineurin Is Essential for PMCA-Mediated Inhibition of Angiogenesis
We previously reported that PMCA4 exerts its negative effects on the calcineurin/NFAT pathway via interaction with calcineurin A. 11 Indeed, disruption of the interaction between endogenous PMCA and calcineurin, by overexpression of the PMCA-interacting domain, strongly increases the activity of the calcineurin/NFAT pathway in breast cancer cells. 21 Therefore, we next assessed whether the PMCA4-mediated negative effect on angiogenesis required interaction between PMCA4 and calcineurin.
For this purpose, we disrupted the interaction between endogenous PMCA4 and calcineurin in HUVECs by infection with adenovirus Ad-ID4 that encodes a Flag-tagged region of PMCA4 encompassing amino acids 428 to 651, corresponding to the domain implicated in the interaction with calcineurin 11 (Figure IVA in the online-only Data Supplement). Plasma membrane-associated proteins were extracted from infected cells using a ProteoExtract Subcellular Proteome Extraction Kit, and the levels of calcineurin were analyzed by Western blot using a monoclonal anticalcineurin antibody. Overexpression of Flag-PMCA4(428-651) resulted in a significant decrease in the levels of calcineurin associated with the plasma membrane ( Figure IVA in the online-only Data Supplement), suggesting that Flag-PMCA4(428-651) was competing with endogenous PMCA4 for binding to calcineurin and, therefore, disrupting the interaction between endogenous PMCA4 and calcineurin. PMCA4 expression in the membrane did not change significantly by infection with Ad-ID4, indicating that the decrease in membrane-associated calcineurin was not a consequence of a reduction in PMCA4 plasma membrane levels after cell infection with Ad-ID4 ( Figure IVA in the online-only Data Supplement).
To discard the possibility that the changes observed in the levels of membrane-associated calcineurin were attributable to downregulation of calcineurin expression in Ad-ID4infected cells, calcineurin total levels were determined by Western blot in proteins from whole-cell lysates. Total levels of calcineurin were equivalent in cells infected with Ad-LacZ or Ad-ID4 ( Figure IVA To quantify the activity of the calcineurin/NFAT pathway in Ad-ID4-transduced HUVECs, cells were further infected with Ad-NFAT-Luc. Measurement of luciferase activity after stimulation of transduced HUVEC with VEGF revealed that Flag-PMCA4(428-651) expression induced a 2.01-fold increase in reporter activity ( Figure 7A ).
Consistent with the results observed in PMCA4 knockout MLECs, disruption of the PMCA4/calcineurin interaction by expression of Flag-PMCA4(428-651) in HUVEC cells resulted in an increase in the basal ( Figure V in the online-only Data Supplement) and VEGF-induced expression of RCAN1.4 ( Figure 7B ). To confirm that the increase in RCAN1.4 expression was a consequence of increased calcineurin activity, through disruption of its interaction with PMCA4, we repeated this assay after preincubation of HUVECs with the calcineurin-inhibitor CsA before VEGF stimulation. As anticipated, CsA pretreatment abrogated not only the VEGF-mediated upregulation of RCAN1.4 expression but also the additional increase promoted by Flag-PMCA4(428-651) ( Figure IVB in the online-only Data Supplement). Collectively, these data indicate that disruption of the PMCA4/calcineurin interaction in endothelial cells eliminates the inhibitory effect of PMCA4, leading to an increase in the activity of the calcineurin/NFAT pathway.
We have shown that overexpression of PMCA4 in HUVECs significantly attenuates RCAN1.4 expression in response to VEGF stimulation (Figure 2A) . To further consider the importance of an intact PMCA4/calcineurin interaction for inhibition of angiogenesis by PMCA4, we examined whether overexpression of PMCA4 could downregulate RCAN1.4 expression under conditions that impaired this interaction. Thus, HUVECs were transduced with both Ad-PMCA4 and Ad-ID4, and RCAN1.4 expression was assessed by Western blot. As expected, disruption of the PMCA4/calcineurin interaction, through overexpression of Flag-PMCA4(428-651), abolished the PMCA4-induced reduction in RCAN1.4 expression ( Figure 7C ), indicating that this interaction is essential for PMCA4-induced inhibition of NFAT-dependent, angiogenic gene expression. In agreement with our previous results illustrating that PMCA4 is not involved in the regulation of the MEK-Erk1/2 pathway (Figure 4) , disruption of the PMCA4/ calcineurin interaction in HUVECs by infection with Ad-ID4 did not alter the activation (phosphorylation) of endothelial Erk1/2 proteins in response to VEGF stimulation ( Figure 7D ).
Finally, we evaluated the significance of the PMCA4/ calcineurin interaction in endothelial cell migration and formation of capillary-like structures. In concurrence with our results in PMCA4 knockout MLEC ( Figure 3B) , disruption of the PMCA4/calcineurin interaction by overexpression of Flag-PMCA4(428-651) augmented endothelial cell motility ( Figure 7E ). Interestingly, ectopic expression of Flag-PMCA4(428-651) significantly increased tube formation in Matrigel assays (even in the absence of VEGF stimulation; Figure 7F ) to a degree similar to that previously observed in cells stimulated with VEGF ( Figure 5A and 5C ). This suggests that enhancement of angiogenesis by blockage of the interaction between PMCA4 and calcineurin might have important therapeutic applications.
Altogether, these data demonstrate that disruption of the PMCA4/calcineurin interaction enhances significantly the activity of the calcineurin/NFAT pathway and consequently the expression of NFAT-dependent, proangiogenic genes, resulting in a significant increase in endothelial cell angiogenesis.
We have reported previously an inhibitory interaction between PMCA4 and endothelial nitric oxide synthase that results in downregulation of nitric oxide production by endothelial cells. 15 PMCA4 also interacts with endothelial nitric oxide synthase through the region 428 to 651, so overexpression of Flag-PMCA4(428-651) might also disrupt the interaction between PMCA4 and endothelial nitric oxide synthase, leading to endothelial nitric oxide synthase activation and an increase in nitric oxide production. It is well established that nitric oxide promotes angiogenesis. 22 Therefore, although our experiments demonstrate the involvement of the calcineurin/ NFAT pathway in the angiogenic increase elicited by Flag-PMCA4(428-651), we cannot rule out that overexpression of this region of PMCA4 may be activating alternative proangiogenic signaling pathways that contribute as well to the observed increase in angiogenesis.
Discussion
In this work, we show that PMCA4 inhibits the activation of the calcineurin/NFAT pathway on VEGF stimulation of endothelial cells, leading to a significant attenuation of VEGF-mediated angiogenesis. Consistent with these findings, PMCA4 has also been shown to play a negative role in the progression of cardiac hypertrophy via downregulation of calcineurin signaling in cardiomyocytes. 16 It is hypothesized that PMCA negatively regulates the activity of calcineurin by recruiting the phosphatase to low-calcium microdomains created by the calcium extrusion ability of the pump. 14 In support of this hypothesis we demonstrate here that the interaction between PMCA4 and calcineurin is essential for the negative effect exerted by PMCA4 on VEGF-induced signaling.
An interaction between calcineurin and calcium influx channels is thought to place the phosphatase into local highcalcium subcellular microdomains that promote activation of calcineurin/NFAT signaling. [23] [24] [25] [26] Here, we show that an interaction between calcineurin and the PMCA4 calcium extrusion pump downregulates calcineurin/NFAT activity. It is therefore tempting to speculate that regulation of calcineurin might involve shuttling between high-and low-calcium subcellular microdomains via interaction with calcium transporters responsible for influx or efflux of calcium. In accord with this notion, activation of the calcineurin/NFAT pathway in cardiomyocytes has been shown to require a calcium signaling microdomain generated by calcium influx from a small fraction of L-type calcium channels specifically housed in caveolae. 27 PMCA4 expression has been localized to lipid rafts and caveolae in endothelial, 28 cardiac, 29 and vascular smooth muscle cells 30 and, interestingly, the calcium-removal function of PMCA4 is impaired in smooth muscle cells of a caveolin-1 knockout mouse. 30 Whether targeting of PMCA4 to caveolae is necessary to downregulate VEGF-induced signaling of the calcineurin/NFAT pathway requires further investigation.
Our data also reveal that PMCA4-mediated inhibition of calcineurin signaling in endothelial cells leads to downregulation of RCAN1.4 and Cox-2 expression, together with an attenuation of VEGF-activated, proangiogenic cellular processes including migration and tubular morphogenesis. Although our results do not directly demonstrate that reduction of these cellular functions is linked to PMCA4-mediated downregulation of RCAN1.4 and Cox-2, both proteins have been described to promote endothelial cell migration and tube formation, 17, 18, 31 suggesting that they likely play a significant role in the PMCA4-directed inhibition of angiogenesis. In agreement with this idea, PMCA4-deficient MLECs presented higher expression of Cox-2 ( Figure IIIB in the online-only Data Supplement) and enhanced cellular migration ( Figure 3B ) than wild-type counterparts. However, specific inhibition of Cox-2 functionality by incubation of PMCA4(−/−) MLECs with the Cox-2 selective inhibitor Etoricoxib resulted in a strong reduction in cell motility ( Figure VI in the online-only Data Supplement), indicating that elevated expression of Cox-2 in PMCA4 knockout cells is linked to their enhanced motility.
The results of our gain-or loss-of-PMCA4 function experiments might be particularly relevant in the context of pathophysiological processes associated with changes in the expression of PMCA proteins. Initial investigations in our laboratory have revealed that stimulation of HUVEC cells with VEGF induces a transient upregulation of PMCA4 protein levels that peaks at 4 to 6 hours after VEGF treatment ( Figure  VII in the online-only Data Supplement). PMCA4 expression has been reported to increase in the late phase of osteoclast differentiation. 32 Interestingly, PMCA4 upregulation in the differentiating osteoclast is dependent on the calcium-triggered activation of the calcineurin/NFAT pathway. In turn, increased osteoclast expression of PMCA4 leads to cytoplasmic calcium removal, creating a negative feedback regulatory loop. 32 Our results suggest that VEGF-induced upregulation of PMCA4 might also be functioning as a negative feedback mechanism to regulate the activation of the calcineurin/NFAT pathway in endothelial cells. Whether VEGF-induced upregulation of PMCA4 in endothelial cells is mediated by NFATdependent transcriptional activation of the PMCA4 gene promoter deserves additional investigation.
Further supporting the functional significance of changes in the expression of PMCA4 in cardiovascular pathophysiology, Ewart et al 33 recently reported that PMCA levels increase in mouse aortic tissue during atherosclerosis.
In this work, we demonstrate that PMCA4 modulates RCAN1.4 expression in endothelial cells through regulation of the calcineurin/NFAT pathway. Interestingly, calcineurindependent expression of RCAN1.4 in other cell types has been linked to pathological vascular wall remodeling 34 and atherosclerosis progression. 35 Hence, the potential role of PMCA4 in the modulation of vascular pathologies linked to RCAN1.4 aberrant expression deserves further investigation.
Although in this study we have focused our attention on isoform PMCA4, we have shown previously that PMCA1 (the other major PMCA isoform expressed in endothelial cells) 13 also interacts with calcineurin in endothelial cells. 15 Thus, partial redundancy between the 2 isoforms might partly mask the total negative effect exerted by PMCA on endothelial calcineurin/NFAT signaling. Nonetheless, our data demonstrate that PMCA4 expression is essential for PMCA-mediated regulation of angiogenesis as suppression of PMCA4 led to a significant enhancement of angiogenesis in spite of background PMCA1 expression. Because targeted ablation of the PMCA1 gene in mice is embryolethal, 36 generation of PMCA1 conditional knockout mice will be required to investigate its potential involvement in the regulation of calcineurin-dependent angiogenesis and to analyze the functional consequences of deleting both isoforms in PMCA1/4 double-knockout animals.
In conclusion, our results describe a novel role for PMCA4 as a negative regulator of VEGF-dependent angiogenesis via interaction with the signaling phosphatase calcineurin.
Given the relevance of the calcineurin/NFAT signaling axis in the regulation of pathological angiogenesis, targeted modulation of PMCA4 functionality might open new therapeutic avenues to promote or attenuate angiogenesis in patients experiencing angiogenic disorders.
